Drug comparisons
Canagliflozin vs Linagliptin
Canagliflozin (Invokana) is an SGLT2 inhibitor for type 2 diabetes; Linagliptin (Tradjenta) is a DPP-4 inhibitor. Compare uses, mechanisms, and safety.
No comparison dimensions are available for this page.
Clinical context
This comparison occurs when selecting between SGLT2 inhibitors and DPP-4 inhibitors for type 2 diabetes treatment.
Bottom line
Canagliflozin and Linagliptin are complementary options for type 2 diabetes with unique benefits and risks rather than one being superior.
All medication comparisons